Bluebird Bio Launches First Gene Therapy for Beta Thalassemia in Germany
bluebird bio gets CHMP nod for gene therapy Zynteglo | Pharmaphorum
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions | Business Wire
Bluebird bio's gene therapy Zynteglo could have high price tag defense in beta thalassemia - Pharmaceutical Technology
SEC Filing - bluebird bio, Inc.
Potential blockbusters make a splash on market entry - Clarivate
FDA Approves bluebird bio's ZYNTEGLO®, the First Gene Therapy for People with Transfusion-Dependent Beta-Thalassemia - The Cooley's Anemia Foundation
bluebird bio to Resume Marketing of ZYNTEGLO in EU
FDA approves bluebird bio's Zynteglo for beta-thalassemia - BIO.News
At $2.8 Million, Beti-cel Is a Canary in the Drug Cost Coal Mine
bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies - Pharmaceutical Technology
FDA Approves Bluebird's $2.8 Million Gene Therapy for Rare Blood Disease - WSJ
SEC Filing - bluebird bio, Inc.
Somerville gene therapy firm bluebird bio nabs win with first FDA approval following split - Boston Business Journal
Bluebird wins U.S. approval for gene therapy for beta thalassemia - STAT
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions - bluebird bio, Inc.
FDA Approves $2.8 million Gene Tx - Zynteglo - Anton Health
Bluebird Bio CEO defends $1.8 million price tag for new gene therapy
bluebird bio Inc., Undervalued Acquisition Candidate (NASDAQ:BLUE) | Seeking Alpha
Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany – TIF
Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRAC
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
